Are we entering the age of $1 million medicine?

d d c z
Credit: Flickr/JohnGoode

More than a quarter of the new medicines approved in the United States last year were designated for rare or so-called orphan diseases. While that’s good news for people suffering from these conditions, the price tags can be overwhelming: The new gene therapy for lipoprotein lipase deficiency is likely to cost more than $1 million per patient when it goes on sale in Europe this summer.  Increasingly, healthcare providers are having to balance the acute needs of the few against the wider interests of society, within constrained budgets.

View the original article here: Are we entering the age of $1 million medicine?

 

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: What are mRNA COVID-19 vaccines and how do they work?

Infographic: What are mRNA COVID-19 vaccines and how do they work?

As of 1 December 2020, thirteen vaccines have reached the final stage of testing: where they are being given to ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend